179 related articles for article (PubMed ID: 20167793)
1. Microdosing for early biokinetic studies in humans.
Stenström K; Sydoff M; Mattsson S
Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
[TBL] [Abstract][Full Text] [Related]
2. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
3. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
[TBL] [Abstract][Full Text] [Related]
5. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
6. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
7. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
Bae SK; Shon JH
Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
[TBL] [Abstract][Full Text] [Related]
8. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
[TBL] [Abstract][Full Text] [Related]
10. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
11. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
Ings RM
Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
[TBL] [Abstract][Full Text] [Related]
12. Optimizing an ultrafast generic high-performance liquid chromatography/tandem mass spectrometry method for faster discovery pharmacokinetic sample throughput.
Dunn-Meynell KW; Wainhaus S; Korfmacher WA
Rapid Commun Mass Spectrom; 2005; 19(20):2905-10. PubMed ID: 16167360
[TBL] [Abstract][Full Text] [Related]
13. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
Barker J; Garner RC
Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
[TBL] [Abstract][Full Text] [Related]
14. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for use in microdosing studies.
Wagner CC; Müller M; Lappin G; Langer O
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
[TBL] [Abstract][Full Text] [Related]
16. High-speed gradient parallel liquid chromatography/tandem mass spectrometry with fully automated sample preparation for bioanalysis: 30 seconds per sample from plasma.
Deng Y; Wu JT; Lloyd TL; Chi CL; Olah TV; Unger SE
Rapid Commun Mass Spectrom; 2002; 16(11):1116-23. PubMed ID: 11992516
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS.
Xu RN; Fan L; Rieser MJ; El-Shourbagy TA
J Pharm Biomed Anal; 2007 Jun; 44(2):342-55. PubMed ID: 17360141
[TBL] [Abstract][Full Text] [Related]
18. The use of accelerator mass spectrometry to obtain early human ADME/PK data.
Lappin G; Garner RC
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):23-31. PubMed ID: 16922650
[TBL] [Abstract][Full Text] [Related]
19. Accelerator mass spectrometry of small biological samples.
Salehpour M; Forsgard N; Possnert G
Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3928-34. PubMed ID: 18980253
[TBL] [Abstract][Full Text] [Related]
20. Direct injection of whole blood for liquid chromatography/tandem mass spectrometry analysis to support single-rodent pharmacokinetic studies.
Ingelse BA; Vogel G; Botterblom M; Nanninga D; Ooms B
Rapid Commun Mass Spectrom; 2008; 22(6):834-40. PubMed ID: 18286667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
